Chemical industry – Page 11
-
BusinessExxonMobil to buy Pioneer for US shale oil dominance
$59 billion deal sees Exxon double its shale oil and gas production
-
BusinessFatal explosion and fire at blending plant in Australia
One worker killed by incident at ACB Group in Melbourne
-
BusinessUS ammonia tanker spill kills five
Seven others hospitalised after traffic incident released 15,000 litres of anhydrous ammonia
-
BusinessChemours is responsible for PFAS pollution, Dutch court rules
Interim decision holds DuPont spin-off liable for environmental damage caused by historical emissions from Dordrecht plant
-
BusinessUS regulator says phenylephrine is ineffective as a decongestant
FDA will begin consultation on removing the drug from hundreds of over-the-counter remedies
-
-
BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
-
ArticleLab Innovations 2023 lays the path for smart and sustainable labs
The UK’s only trade fair for the whole lab industry forges the way to sustainability and innovation
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
-
BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
-
BusinessLapsed US chemical security programme leaves facilities vulnerable
Chemical Facility Anti-Terrorism Standards’ expiry means rules will not be enforced, and companies cannot vet new staff
-
NewsEuropean intellectual property system ready for gene-edited crops
Updates to New Genomic Technology regulations irrelevant to IP say experts
-
FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
ArticleCPHI Barcelona 2023: forging collaborations for a promising future in the pharmaceutical sector
CPHI creates connections and inspires partnerships across the global pharma community
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail